胰腺癌立体定向磁共振引导放疗的多参数预后模型开发
本研究纳入83例不可切除胰腺导管腺癌患者,基于临床特征、SMART剂量学数据及0.35-T模拟MRI影像组学数据,采用机器学习算法构建总生存(OS)和局部控制(LC)的多参数预后模型。OS最佳模型为Cox比例风险模型(C-index IPCW 0.87),LC最佳模型为component-wise梯度提升生存分析(C-index IPCW 0.80)。结论认为联合临床与影像组学数据构建的多参数预后模型对OS和LC预测表现良好,尚需外部验证。
要点
- 83例不可切除胰腺导管腺癌患者接受SMART,中位年龄64.9岁,77%为局部晚期。
- SMART完成后中位OS为21个月,6个月和12个月OS分别为87.8%和70.9%。
- OS最佳模型为Cox模型(C-index IPCW 0.87),LC最佳模型为梯度提升生存分析(C-index IPCW 0.80)。
核心结论
- 联合临床与影像组学数据、使用机器学习算法构建的多参数预后模型对SMART治疗不可切除胰腺导管腺癌的OS和LC预测表现良好,尚需外部验证。
主要发现
- 83例患者中位年龄64.9岁,77%为局部晚期胰腺癌;SMART完成后中位OS为21个月,化疗开始后中位OS为27个月。
- SMART后6个月和12个月OS分别为87.8%(95%CI 78.2%-93.2%)和70.9%(95%CI 58.8%-80.0%)。
- OS最佳模型为使用临床数据的Cox比例风险生存分析,C-index IPCW为0.87;12个月OS预测的敏感度67%、特异度71%、AUC 0.90。
- 中位LC未达到;SMART后6个月和12个月LC分别为92.4%(95%CI 83.7%-96.6%)和76.3%(95%CI 62.6%-85.5%)。
- LC最佳模型为使用临床和影像组学数据的component-wise梯度提升生存分析,C-index IPCW为0.80;9个月LC预测的敏感度50%、特异度97%、AUC 0.78。
关键数值与推荐
- OS最佳模型:Cox比例风险生存分析(临床数据),C-index IPCW 0.87;12个月OS预测敏感度67%、特异度71%、AUC 0.90。
- LC最佳模型:component-wise梯度提升生存分析(临床+影像组学数据),C-index IPCW 0.80;9个月LC预测敏感度50%、特异度97%、AUC 0.78。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic magnetic resonance guided adaptive radiation therapy (SMART) is a new option for local treatment of unresectable pancreatic ductal adenocarcinoma, showing interesting survival and local control (LC) results. Despite this, some patients will experience early local and/or metastatic recurrence leading to death. We aimed to develop multiparametric prognostic models for these patients. METHODS AND MATERIALS: All patients treated in our institution with SMART for an unresectable pancreatic ductal adenocarcinoma between October 21, 2019, and August 5, 2022 were included. Several initial clinical characteristics as well as dosimetric data of SMART were recorded. Radiomics data from 0.35-T simulation magnetic resonance imaging were extracted. All these data were combined to build prognostic models of overall survival (OS) and LC using machine learning algorithms. RESULTS: Eighty-three patients with a median age of 64.9 years were included. A majority of patients had a locally advanced pancreatic cancer (77%). The median OS was 21 months after SMART completion and 27 months after chemotherapy initiation. The 6- and 12-month post-SMART OS was 87.8% (IC95%, 78.2%-93.2%) and 70.9% (IC95%, 58.8%-80.0%), respectively. The best model for OS was the Cox proportional hazard survival analysis using clinical data, with a concordance index inverse probability of censoring weighted of 0.87. Tested on its 12-month OS prediction capacity, this model had good performance (sensitivity 67%, specificity 71%, and area under the curve 0.90). The median LC was not reached. The 6- and 12-month post-SMART LC was 92.4% [IC95%, 83.7%-96.6%] and 76.3% [IC95%, 62.6%-85.5%], respectively. The best model for LC was the component-wise gradient boosting survival analysis using clinical and radiomics data, with a concordance index inverse probability of censoring weighted of 0.80. Tested on its 9-month LC prediction capacity, this model had good performance (sensitivity 50%, specificity 97%, and area under the curve 0.78). CONCLUSIONS: Combining clinical and radiomics data in multiparametric prognostic models using machine learning algorithms showed good performance for the prediction of OS and LC. External validation of these models will be needed.
引用
- Michalet M, Valenzuela G, Nougaret S, et al. Development of Multiparametric Prognostic Models for Stereotactic Magnetic Resonance Guided Radiation Therapy of Pancreatic Cancers. Int J Radiat Oncol Biol Phys. 2025. PMID: 40185208. doi:10.1016/j.ijrobp.2025.03.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。